{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:45:00Z","timestamp":1776689100243,"version":"3.51.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,21]]},"DOI":"10.1093\/eurheartj\/eht428","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T20:18:43Z","timestamp":1381954723000},"page":"233-241","source":"Crossref","is-referenced-by-count":82,"title":["Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial"],"prefix":"10.1093","volume":"35","author":[{"given":"Kenneth W.","family":"Mahaffey","sequence":"first","affiliation":[{"name":"Department of Medicine, Stanford University, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna R.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Nessel","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Hacke","sequence":"additional","affiliation":[{"name":"Ruprecht-Karls-University, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme J.","family":"Hankey","sequence":"additional","affiliation":[{"name":"Royal Perth Hospital, Perth, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[{"name":"Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[{"name":"University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Breithardt","sequence":"additional","affiliation":[{"name":"Hospital of the University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the ROCKET AF Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,10,15]]},"reference":[{"key":"key\n\t\t\t\t20180328173226_EHT428C1","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328173226_EHT428C2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study","volume":"147","author":"Wolf","year":"1987","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcad.2005.06.001","article-title":"Epidemiological profile of atrial fibrillation: a contemporary perspective","volume":"48","author":"Tsang","year":"2005","journal-title":"Prog Cardiovasc Dis"},{"key":"key\n\t\t\t\t20180328173226_EHT428C5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C6","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2006.10.062","article-title":"Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study","volume":"49","author":"Miyasaka","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328173226_EHT428C7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1540-8167.2002.00399.x","article-title":"Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets","volume":"13","author":"Ehrlich","year":"2002","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key\n\t\t\t\t20180328173226_EHT428C8","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1161\/01.CIR.0000132470.78896.A8","article-title":"Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle","volume":"109","author":"Cha","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C9","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.CIR.101.9.969","article-title":"Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes","volume":"101","author":"Rathore","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1540-8159.1983.tb06581.x","article-title":"Atrial tachycardia facilitating initiation of ventricular tachycardia","volume":"6","author":"Roy","year":"1983","journal-title":"Pacing Clin Electrophysiol"},{"key":"key\n\t\t\t\t20180328173226_EHT428C12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1046\/j.1540-8167.2000.01208.x","article-title":"Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study","volume":"11","author":"Gronefeld","year":"2000","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key\n\t\t\t\t20180328173226_EHT428C13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(01)06585-0","article-title":"Acute coronary syndrome without ST elevation: implementation of new guidelines","volume":"358","author":"Hamm","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328173226_EHT428C14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1067\/mhj.2000.111108","article-title":"New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience","volume":"140","author":"Wong","year":"2000","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180328173226_EHT428C15","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","article-title":"2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation","volume":"123","author":"ACCF\/AHA Task Force","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C16","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the ESC","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328173226_EHT428C17","first-page":"645","article-title":"2012 ACCF\/AHA focused update on the guideline for the management of patients with unstable angina\/non-ST-elevation myocardial infarction","volume":"60","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328173226_EHT428C18","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Antithrombotic therapy and prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180328173226_EHT428C19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCINTERVENTIONS.111.965186","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary","volume":"4","author":"Faxon","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328173226_EHT428C20","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.109.924944","article-title":"Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents","volume":"121","author":"Paikin","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C21","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/heart.88.4.357","article-title":"Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience","volume":"88","author":"Wong","year":"2002","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180328173226_EHT428C23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study","volume":"159","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180328173226_EHT428C25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328173226_EHT428C26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C30","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/archinternmed.2011.1721","article-title":"Dabigatran: do we have sufficient data?: comment on \u2018Dabigatran association with higher risk of acute coronary events","volume":"172","author":"Jacobs","year":"2012","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328173226_EHT428C33","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328173226_EHT428C34","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/eurheartj\/ehq117","article-title":"Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing coronary stenting: executive summary\u2014a Consensus Document of the European Society of Cardiology Working Group on Thrombosis","volume":"31","author":"Lip","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328173226_EHT428C35","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328173226_EHT428C36"},{"key":"key\n\t\t\t\t20180328173226_EHT428C37"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/35\/4\/233\/17354916\/eht428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T02:42:38Z","timestamp":1522291358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/35\/4\/233\/466337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,10,15]]},"published-print":{"date-parts":[[2014,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/eht428","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,1,21]]},"published":{"date-parts":[[2013,10,15]]}}}